Call Us For More Information


Two Novel Molecules: VY-OZ and VY-X

Vycellix is advancing its proprietary pipeline of novel immunomodulators in pursuing three initial commercial pathways to establish these products as: 1) platform technology for the efficient, cost-effective modulation of cell and gene therapies, 2) monotherapy and/or adjuvant therapeutics targeting cancers and infectious disease, and; 3) enhancers of gene editing for CRISPR-Cas9 systems.


Comments are closed.